Three consecutive Data Safety Monitoring Committee reviews without a single protocol modification is not a routine milestone — it is a structural argument. Across more than 190 patients in four completed clinical trials and now a fully enrolled Phase 3 population exceeding 900 randomized participants, DURAVYU has yet to generate a drug-related safety signal serious enough to prompt independent experts to change course. That consistency matters because vorolanib‘s multi-target mechanism — inhibiting all VEGF receptors, PDGFR, and IL-6/JAK1 simultaneously — raised legitimate questions early on about whether broader intracellular suppression would carry a broader adverse event profile. Three clean DSMC cycles later, that concern has not materialized.
The enrollment architecture of LUGANO and LUCIA rewards scrutiny. Both trials randomize 1:1 to DURAVYU 2.7 mg every six months versus on-label aflibercept, and the primary endpoint is non-inferiority in mean BCVA change averaged across weeks 52 and 56. Non-inferiority designs live and die on margin selection and completion rates, but EyePoint has built in a secondary endpoint that does the real competitive work: percentage of eyes free of supplemental aflibercept injections. If the BCVA non-inferiority holds and the injection-burden reduction is substantial, the label argument essentially writes itself against a standard of care that currently demands treatment roughly every eight weeks under treat-and-extend. The fact that all active treatment-arm patients have hit their Week 32 second-dose visit, with over 35% already receiving a third dose at Week 56, confirms the dosing cadence is functionally achievable — not just theoretically attractive.
The competitive context is unforgiving. Faricimab established dual-mechanism credibility and six-to-sixteen week dosing flexibility; port delivery systems have attempted to solve the injection burden problem through hardware rather than pharmacology. DURAVYU is threading a different needle — a bioerodible insert delivering a small-molecule TKI on a fixed six-month schedule, with no reservoir refill and no free-floating particles. The Phase 2 DAVIO trial hit statistically positive results against aflibercept, which is what justified this Phase 3 design. That prior evidence provides a legitimate prior probability of success, but non-inferiority trials can fail on execution even when biology cooperates.
LUGANO topline data arriving mid-2026 is now the single number that resolves everything else — the mechanism argument, the dosing-burden narrative, and EyePoint’s commercial viability as a standalone entity. Watch the supplemental injection rate in the DURAVYU arm: if it comes in below 20%, the label differentiation from faricimab becomes concrete and the payer conversation changes fundamentally.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
